Phar 7.06(4)(b)3. 3. Name of manufacturer or distributer of the drug product, and the manufacturer lot number.

Phar 7.06(5) (5) Records of all repackaging for stock operations are maintained and include all the following:

Phar 7.06(5)(a) (a) Name, strength, form, quantity per container, and quantity of containers.

Phar 7.06(5)(b) (b) NDC number or the name of the manufacturer or distributor of the drug product.

Phar 7.06(5)(c) (c) Manufacturer lot number.

Phar 7.06(5)(d) (d) Original container’s expiration date and the beyond-use date for the new containers.

Phar 7.06(5)(e) (e) First and last name of the pharmacist or delegate that repackaged the drug and the first and last name of the pharmacist that verified the accuracy of the repackaging.

Phar 7.06(5)(f) (f) Date of repackaging.

Phar 7.06(5)(g) (g) Any pharmacy control numbers.

Phar 7.06 History History: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21.

Phar 7.07 Phar 7.07 Final check.

Phar 7.07(1) (1) A final check of accuracy and correctness is required for any prescription drug product or device dispensed and shall include all of the following:

Phar 7.07(1)(a) (a) Verifying label is correct and meets labeling requirements.

Phar 7.07(1)(b) (b) Verifying the drug product or device is correct.

Phar 7.07(1)(c) (c) Completion of the drug utilization review.

Phar 7.07(2) (2) For all prescription drug products or devices dispensed by a pharmacist, the prescription record shall identify the pharmacist responsible for each part of the final check. If sub. (1) (a) or (b) is completed by a pharmacy product verification technician under s. Phar 7.14 or automated technology under s. Phar 7.55, the prescription record shall identify the pharmacy product verification technician performing the check.

Phar 7.07 History History: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21; EmR2303: emerg. am. (2), eff. 2-3-23; CR 23-072: am. (2) Register August 2024 No. 824, eff 9-1-24.

Phar 7.08 Phar 7.08 Patient consultation.

Phar 7.08(1) (1) A pharmacist shall provide the patient or patient’s agent consultation to optimize proper use of a prescription drug or device, that meets any of the following:

Phar 7.08(1)(a) (a) Has not been dispensed previously to the patient.

Phar 7.08(1)(b) (b) Is a change in therapy.

Phar 7.08(1)(c) (c) Upon request of a patient or patient’s agent.

Phar 7.08(1)(d) (d) Whenever deemed necessary based upon the professional judgement of the dispensing pharmacist.

Phar 7.08(2) (2) Notwithstanding sub. (1), consultation is not required when one of the following occurs:

Phar 7.08(2)(a) (a) A drug or device will be administered, by ingestion, inhalation, injection, or any other route, by or in the presence of one of the following:

Phar 7.08(2)(a)1. 1. An individual with a scope of practice that includes the administration of a drug or device.

Phar 7.08(2)(a)2. 2. A delegate of an individual with authority to delegate the administration of a drug or device.

Phar 7.08(2)(b) (b) A patient or patient’s agent refuses consultation.

Phar 7.08(3) (3) Consultation shall contain any of the following information that, in the pharmacist’s professional judgment, serves the best interest of the patient: